home / stock / ettx / ettx news

ETTX News and Press, Entasis Therapeutics Holdings Inc. From 10/03/19

Stock Information
Company Name: Entasis Therapeutics Holdings Inc.
Stock Symbol: ETTX
Market: NASDAQ
Website: entasistx.com
Menu
ETTX ETTX Quote ETTX Short ETTX News ETTX Articles ETTX Message Board
Get ETTX Alerts

News, Short Squeeze, Breakout and More Instantly...
ETTX - Entasis Therapeutics Announces Multiple Presentations at ID Week 2019

WALTHAM, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced its participation in an industry panel presen...
ETTX - Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

WASHINGTON , Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies will present data from their clinical ...

ETTX - GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea

Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care 87 million new gonorrhea infections estimated each year; Neisseria gonorrhoeae increasingly resistant to globally recomme...

ETTX - Entasis Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Off...
ETTX - Entasis Therapeutics reports Q2 results

Entasis Therapeutics (NASDAQ: ETTX ): Q2 GAAP EPS of -$1.02. More news on: Entasis Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...

ETTX - Entasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its second quarter financial results ended June 30, 2019 and pr...

ETTX - Entasis Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

WALTHAM, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Offi...
ETTX - Entasis Therapeutics Appoints Dr. Howard Mayer to Board of Directors

WALTHAM, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the appointment of Howard Mayer, M.D to its board of dire...

ETTX - X-Biotix Therapeutics Joins Antimicrobials Working Group

WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new additi...

ETTX - X-Biotix Therapeutics Joins Antimicrobials Working Group

WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new additi...
Previous 10 Next 10